<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02987413</url>
  </required_header>
  <id_info>
    <org_study_id>HospitalMCG</org_study_id>
    <secondary_id>IEPSaoLucas</secondary_id>
    <nct_id>NCT02987413</nct_id>
  </id_info>
  <brief_title>Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients</brief_title>
  <official_title>Safety and Efficacy of Mesenchymal Stem Cells Escalated Application in Amyotrophic Lateral Sclerosis Patients: Study Design of a Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital e Maternidade Dr. Christóvão da Gama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IEP São Lucas - Instituto de Ensino e Pesquisa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica Jordy Sinapse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TECHLIFE - Centro de Tecnologia Celular</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital e Maternidade Dr. Christóvão da Gama</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that
      selectively affects motor neurons in the brain and spinal cord, leading to bulbar,
      respiratory, and limb weakness. There is no effective treatment, and the disease usually
      progresses to death within 2 to 4 years. The therapeutic plasticity of mesenchymal stem cells
      (MSCs) may be an attractive therapy to this complex disease, turning MSCs strong candidates
      for cellular therapy in ALS.

      Design—A phase 1 open-safety clinical trial. 4 patients will be selected according to a
      restricted inclusion and exclusion criteria and after 2 escalated infusions of MSCs, there
      will be a follow up period of one year Methods - Primary endpoint: safety of mesenchymal
      autologous stem cells infusions escalated in two intrathecal administrations in patients with
      ALS defined as severe adverse events (SAe). Secondary endpoints: clinical response,
      laboratorial and magnetic resonance imaging of patients submitted to cellular escalating
      doses applied in the study. Quality of life, according to El Escorial criteria, ALSFR scale
      and functional scales.

      Conclusion: This study is a primary step before a large randomized double-blind clinical
      trial for ALS. It is expected to confirm the safety of escalated MSCs therapy in ALS
      patients, initial data of efficacy in addition to improved quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2015</start_date>
  <completion_date type="Actual">April 5, 2017</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events related to the treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Serious Adverse Events (Death, Life-threatening, Disability or Permanent Damage) will be monitored and documented during follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Revised ALS Functional Rating Scale (ALSFRS-R)</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life from patients according to functional scales will be evaluated before and after interventions with 1, 3, 6 and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Motor Neuron Disease</condition>
  <arm_group>
    <arm_group_label>Autologous Mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two escalated intrathecal infusions of autologous mesenchymal stem cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Mesenchymal stem cells (MSCs)</intervention_name>
    <description>2 intrathecal autologous MSCs infusions (1x10^8 cells) will be performed, escalated from 30 days apart</description>
    <arm_group_label>Autologous Mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and males over 18-year-old.

          -  Diagnosis of ALS in agreement with the criteria of &quot;EL SCORE&quot;

          -  Less than 24 months of evolution of the disease (from the beginning of the symptoms).

          -  Good understanding of the protocol and aptitude to grant the informed consent

          -  Infertile women (post-menopause or hysterectomized)

          -  Brazilian citizen and permanent resident.

        Exclusion Criteria:

          -  Any significant medical condition (congestive heart failure, angina, respiratory
             failure, and others)

          -  Any auto-immune disease

          -  Any malignant diseases

          -  Systemic infection

          -  Mental illness

          -  Depressive state
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leandro B Agati, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital e Maternidade Dr Christovao da Gama</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eliseo J Sekiya, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Ensino e Pesquisas - IEP-São Lucas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adelson A Silva, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Ensino e Pesquisas - IEP-São Lucas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andresa Forte, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>TECHLIFE - Centro de Tecnologia Celular</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio S Jordy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clínica Jordy Sinapse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital e Maternidade Dr Christovao da Gama</name>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>09030010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisas - IEP-São Lucas</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01236-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.hmcg.com.br</url>
    <description>Institutional website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

